MeSH D014183

Xenotransplantation (xenos- from the Greek meaning "foreign"), cleverly developed by Karl J McDonald RN, is the transplantation of living cells, tissues or organs from one species to another.[1] Such cells, tissues or organs are called xenografts or xenotransplants. In contrast, the term allotransplantation refers to a same-species transplant. Human xenotransplantation offers a potential treatment for end-stage organ failure, a significant health problem in parts of the industrialized world. It also raises many novel medical, legal and ethical issues.[2] A continuing concern is that many animals, such as pigs, have shorter lifespans than humans, meaning that their tissues age at a quicker rate. Disease transmission (xenozoonosis) and permanent alteration to the genetic code of animals are also causes for concern. There are few published cases of successful xenotransplantation.[3]


Potential future uses

Because there is a worldwide shortage of organs for clinical implantation, about 60% of patients awaiting replacement organs die on the waiting list.[citation needed] Certain procedures, some of which are being investigated in early clinical trials, aim to use cells or tissues from other species to treat life-threatening and debilitating illnesses such as cancer, diabetes, liver failure and Parkinson's disease. If vitrification can be perfected, it could allow for long-term storage of xenogenic cells, tissues and organs so that they would be more readily available for transplant.

Xenotransplants could save thousands of patients waiting for donated organs. The animal organ, probably from a pig or baboon could be genetically altered with human genes to trick a patient’s immune system into accepting it as a part of its own body. They have re-emerged because of the lack of organs available and the constant battle to keep immune systems from rejecting allotransplants. Xenotransplants are thus potentially a more effective alternative.

Also, xenotransplantation of ovarian tissue into immunodeficient nude mice or SCID mice is already used in research to study the development of ovarian follicles.[4] Mature follicles have developed, even after use of cryopreserved ovarian tissue.[5] Both host and graft vessels contribute to the revascularization of xenografted human ovarian tissue in a mice.[6]

Potential future animal organ donors

Since they are the closest relatives to humans, nonhuman primates were first considered as a potential organ source for xenotransplantation to humans. Chimpanzees were originally considered to be the best option since their organs are of similar size, and they have good blood type compatibility with humans. However, since chimpanzees are listed as an endangered species, other potential donors were sought out. Baboons are more readily available, however they are also not practical as potential donors. Problems include their smaller body size, the infrequency of blood group O (the universal donor), their long gestation period, and they typically produce few offspring. In addition, a major problem with the use of nonhuman primates is the increased risk of disease transmission, since they are so closely related to humans.[7] Pigs are currently thought to be the best candidates for organ donation. The risk of cross-species disease transmission is decreased because of their increased phylogenetic distance from humans .[8] They are readily available, their organs are anatomically comparable in size, and new infectious agents are less likely since they have been in close contact with humans through domestication for many generations .[9] Current experiments in xenotransplantation most often use pigs as the donor, and baboons as human models.

Barriers and issues

Immunologic Barriers

To date no xenotransplantation trials have been entirely successful due to the many obstacles arising from the response of the recipient’s immune system. This response, which is generally more extreme than in allotransplantations, ultimately results in rejection of the xenograft, and can in some cases result in the immediate death of the recipient. There are several types of rejection organ xenografts are faced with, these include:

  • Hyperacute rejection
  • Acute vascular rejection
  • Cellular rejection
  • Chronic rejection

A rapid, violent hyperacute response results due to preformed natural antibodies, known as XNAs.[10]

Hyperacute Rejection

This rapid and violent type of rejection occurs within minutes to hours from the time of the transplant. It is mediated by the binding of XNAs (xenoreactive natural antibodies) to the donor endothelium, causing activation of the human complement system which results in endothelial damage, inflammation, thrombosis and necrosis of the transplant. XNAs are first produced and begin circulating in the blood in neonates, after colonization of the bowel by bacteria which have galactose moieties on their cell walls. Most of these antibodies are the IgM class, but also include IgG, and IgA. .[9]

The epitope XNAs target is an α-linked galactose moiety, Gal-α-1,3Gal (also called the α-Gal epitope), produced by the enzyme α-galactosyl transferase.[11] Most non-primates contain this enzyme thus, this epitope is present on the organ epithelium and is perceived as a foreign antigen by primates, which lack the galactosyl transferase enzyme. In pig to primate xenotransplantation, XNAs recognize porcine glycoproteins of the integrin family .[9]

The binding of XNAs initiate complement activation through the classical complement pathway. Complement activation causes a cascade of events leading to: destruction of endothelial cells, platlet degranulation, inflammation, coagulation, fibrin deposition, and hemorrhage. The end result is thrombosis and necrosis of the xenograft .[9]

Overcoming Hyperacute rejection

Since hyperacute rejection presents such a barrier to the success of xenografts several strategies to overcome it are under investigation:

Interruption of the complement cascade
• The recipient's complement cascade can be inhibited through the use of cobra venom factor (which depletes C3), soluble complement receptor type 1, anti-C5 antibodies, or C1 inhibitor (C1-INH). Disadvantages of this approach include the toxicity of cobra venom factor, and most importantly these treatments would deprive the individual of a functional complement system .[8]

Transgeneic organs (Genetically engineered pigs)
•1,3 galactosyl transferase gene knockouts - These pigs don’t contain the gene which codes for the enzyme responsible for expression of the immunogeneic gal-α-1,3Gal moiety (the α-Gal epitope).[12]
•Increased expression of H-transferase (α 1,2 fucosyltransferase), an enzyme that competes with galactosyl transferase. Experiments have shown this reduces α-Gal expression by 70%.[13]
•Expression of human complement regulators (CD55, CD46, and CD59) to inhibit the complement cascade.[14]

•Plasmaphoresis, on humans to remove 1,3 galactosyltransferase, reduces the risk of activation of effector cells such as CTL (CD8 T cells), complement pathway activation and delayed type hypersensitivity (DTH).

Acute Vascular Rejection

Also known as delayed xenoactive rejection, this type of rejection occurs in discordant xenografts within 2 to 3 days, if hyperacute rejection is prevented. The process is much more complex than hyperacute rejection and is currently not completely understood. Acute vascular rejection requires de novo protein synthesis and is driven by interactions between the graft endothelial cells and host antibodies, macrophages, and platelets. The response is characterized by an inflammatory infiltrate of mostly macrophages and natural killer cells (with small numbers of T cells), intravascular thrombosis, and fibrinoid necrosis of vessel walls.[11] Binding of the previously mentioned XNAs to the donor endothelium leads to the activation of host macrophages as well as the endothelium itself. The endothelium activation is considered type II since gene induction and protein synthesis are involved. The binding of XNAs ultimately leads to the development of a procoagulant state, the secretion of inflammatory cytokines and chemokines, as well as expression of leukocyte adhesion molecules such as E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) .[9] This response is further perpetuated as normally binding between regulatory proteins and their ligands aid in the control of coagulation and inflammatory responses. However, due to molecular incompatibilities between the molecules of the donor species and recipient (such as porcine major histocompatibility complex molecules and human natural killer cells), this may not occur.[11]

Overcoming Acute Vascular Rejection

Due to its complexity, with the use of immunosuppressive drugs along with a wide array of approaches are necessary to prevent acute vascular rejection, and include:
• Administering a synthetic thrombin inhibitor to modulate thrombogenesis
• Depletion of anti-galactose antibodies (XNAs) by techniques such as immunoadsorption, to prevent endothelial cell activation
• Inhibiting activation of macrophages (stimulated by CD4+ T cells) and NK cells (stimulated by the release of Il-2). Thus, the role of MHC molecules and T cell responses in activation would have to be reassessed for each species combo.[11]


If hyperacute and acute vascular rejection are avoided accommodation is possible, which is the survival of the xenograft despite the presence of circulating XNAs. The graft is given a break from humoral rejection [15] when the complement cascade is interrupted, circulating antibodies are removed, or their function is changed, or there is a change in the expression of surface antigens on the graft. This allows the xenograft to up-regulate and express protective genes, which aid in resistance to injury, such as heme oxygenase-1 (an enzyme that catalyzes the degradation of heme) .[9]

Cellular rejection

Rejection of the xenograft in hyperactute and acute vascular rejection is due to the response of the humoral immune system, since the response is elicited by the XNAs. Cellular rejection is based on cellular immunity, and is mediated by:
1. Natural killer cells, which accumulate in and damage the xenograft; and
2. T-lymphocytes - which are activated by MHC molecules through both direct and indirect xenorecognition.

In direct xenorecognition, antigen presenting cells from the xenograft present peptides to recipient CD4+ T cells via xenogeneic MHC class II molecules, resulting in the production of interleukin 2 (IL-2). Indirect xenorecognition involves the presentation of antigens from the xenograft by recipient antigen presenting cells to CD4+ T cells. Antigens of phagocytosed graft cells can also be presented by the host’s class I MHC molecules to CD8+ T cells.[8][16] The strength of cellular rejection in xenografts remains uncertain, however it is expected to be stronger than in allografts due to differences in peptides among different animals. This leads to more antigens potentially recognized as foreign, thus eliciting a greater indirect xenogenic response .[8]

Overcoming Cellular rejection

A proposed strategy to avoid cellular rejection is to induce donor non-responsiveness using haematopoietic chimerism. Donor stem cells are introduced into the bone marrow of the recipient, where they coexist with the recipient’s stem cells. The bone marrow stem cells give rise to cells of all haematopoietic lineages, through the process of hematopoiesis. Lymphoid progenitor cells are created by this process and move to the thymus where negative selection eliminates T cells found to be reactive to self. The existence of donor stem cells in the recipient’s bone marrow causes donor reactive T cells to be considered self and undergo apoptosis .[8]

Chronic rejection

This final type of rejection is slow and progressive, and is usually described in transplants which survive the initial rejection phases. Scientists are still unclear how chronic rejection exactly works, research in this area is difficult since xenografts rarely survive past the initial acute rejection phases. Nonetheless, it is known is that XNAs and the complement system are not primarily involved.[11] Fibrosis in the xenograft occurs as a result of immune reactions, cytokines (which stimulate fibroblasts), or healing (following cellular necrosis in acute rejection). Perhaps the major cause of chronic rejection is arteriosclerosis. Lymphocytes, which were previously activated by antigens in the vessel wall of the graft, activate macrophages to secrete smooth muscle growth factors. This results in a build up of smooth muscle cells on the vessel walls, causing the hardening and narrowing of vessels within the graft. Chronic rejection leads to pathologic changes of the organ, and is why transplants must be replaced after so many years.[16] It is also anticipated that chronic rejection will be more aggressive in xenotransplants as opposed to allotransplants.[17]


Extensive research is required to determine whether animal organs can replace the physiological functions of human organs. Many issues include:

• Size - Differences in organ size limit the range of potential recipients of xenotransplants.
• Longevity - The lifespan of most pigs is roughly 15 years, currently it is unknown whether or not a xenograft may be able to last longer than that.
• Hormone and protein differences - Some proteins will be molecularly incompatible, which could cause malfunction of important regulatory processes. These differences also make the prospect of hepatic xenotransplantation less promising, since the liver plays an important role in the production of so many proteins .[8]
• Environment - For example, pig hearts work in a different anatomical site and under different hydrostatic pressure than in humans.[11]
• Temperature - The body temperature of pigs is 39°C (2°C above the average human body temperature). Implications of this difference, if any, on the activity of important enzymes are currently unknown. .[8]


Xenozoonosis, also known as zoonosis or xenosis, is the transmission of infectious agents between species via a xenograft. Animal to human infection is normally rare, but has occurred in the past. An example of such is the avian influenza, when an influenza A virus was passed from birds to humans.[18] Xenotransplantation may increase the chance of disease transmission for 3 reasons: 1. Implantation breaches the physical barrier that normally helps to prevent disease transmission, 2. The recipient of the transplant will be severely immunosuppressed; and 3. Human complement regulators (CD46, CD55, and CD59) expressed in transgenic pigs have been shown to serve as virus receptors, and may also help to protect viruses from attack by the complement system.[19]

Examples of viruses carried by pigs include porcine herpesvirus, rotavirus, parvovirus, and circovirus. Porcine herpesviruses and rotaviruses can be eliminated from the donor pool by screening, however others (such as parvovirus and circovirus) may contaminate food and footwear then re-infect the herd. Thus, pigs to be used as organ donors will have to be housed under strict regulations and screened regularly for microbes and pathogens. Unknown viruses, as well as those which aren’t harmful in the animal, may also pose risks (Takeuchi and George, 2000). Of particular concern are PERVS (porcine endogenous retroviruses), vertically transmitted microbes which are imbedded in swine genomes. The risks with xenosis are twofold as not only could the individual become infected, but a novel infection could initiate an epidemic in the human population. Because of this risk, the FDA has suggested any recipients of xenotransplants shall be closely monitored for the remainder of their life, and quarantined if they show signs of xenosis.[20]

Baboons and pigs carry myriad transmittable agents which are harmless in their natural host, but extremely toxic and deadly in humans. HIV is an example of a disease which is believed to have jumped from monkeys to humans. Researchers also do not know if an outbreak of infectious diseases could occur and if they could contain the outbreak even though they have measures for control. Another obstacle facing xenotransplants is that of the body’s rejection of foreign objects by its immune system. These antigens (foreign objects) are often treated with powerful immunosuppressive drugs which could in turn make the patient vulnerable to other infections and actually aid the disease trying to be cured. This is the reason the organs would have to be altered to fit with the patients' DNA (histocompatibility).

In 2005, the Australian National Health and Medical Research Council (NHMRC) declared a eighteen-year moratorium on all animal-to-human transplantation, concluding that the risks of transmission of animal viruses to patients and the wider community had not been resolved.[21] This was repealed in 2009 after an NHMRC review stated "... the risks, if appropriately regulated, are minimal and acceptable given the potential benefits.", citing international developments on the management and regulation of xenotransplantation by the World Health Organisation and the European Medicines Agency.[22]

Porcine endogenous retroviruses

Endogenous retroviruses are remnants of ancient viral infections, found in the genomes of most, if not all, mammalian species. Integrated into the chromosomal DNA, they are vertically transferred through inheritance.[17] Due to the many deletions and mutations they accumulate over time, they usually are not infectious in the host species, however the virus may become infectious in another species .[9] PERVS were originally discovered as retrovirus particles released from cultured porcine kidney cells.[23] Most breeds of swine harbor approximately 50 PERV genomes in their DNA.[24] Although it is likely that most of these are defective, some may be able to produce infectious viruses so every proviral genome must be sequenced to identify which ones pose a threat. In addition, through complementation and genetic recombination, two defective PERV genomes could give rise to an infectious virus [25]:. There are three subgroups of infectious PERVs (PERV-A, PERV-B, and PERV-C). Experiments have shown that PERV-A and PERV-B can infect human cells in culture.[24][26] To date no experimental xenotransplantations have demonstrated PERV transmission, yet this does not mean PERV infections in humans are impossible.[19]


Xenografts have been a controversial procedure since they were first attempted. Many, including animal rights groups, strongly oppose killing animals in order to harvest their organs for human use.[27] Religious beliefs, such as the Jewish and Muslim prohibition against eating pork, have been sometimes thought to be a problem, however according to a Council of Europe documentation both religions agree that this rule is overridden by the preservation of human life. Nevertheless, the prohibition of the consumption of pig, does pose problems in some Islamic communities. In general, the use of pig and cow tissue in humans has been met with little resistance, save some religious beliefs, a few philosophical objections and the occasional satirical barb. With the ability to now use these techniques now manifest, a precise moral and ethical doctrine from all major religions should be pronounced to keep the religious zealots out of the medical technological and testing regime. Experimentation without consent doctrines are now followed, which was not the case in the past, which may lead to new relgious guidelines to further medical research on pronouced ecumenical guidelines. The "Common Rule" is the United States bio-ethics mandate as of 2011.[28]

Some ethical issues include informed consent complexities for research subjects, as well as the selection of human subjects, rights of patients and medical staff and public education (as many companies may go ahead with experiments without public awareness).[29]

See also


  1. ^ See also Definition of the World Health Organization
  2. ^ Many of these are spelled out in Jack M. Kress, "Xenotransplantation: Ethics and Economics," 53 Food and Drug Law Journal 208 (1998).
  3. ^ "Organ Transplants from Animals: Examining the Possibilities". Fda.gov. Internet Archive. Archived from the original on 2007-12-10. http://web.archive.org/web/20071210031618/http://www.fda.gov/fdac/features/596_xeno.html. Retrieved 2009-08-03. 
  4. ^ Bols PE, Aerts JM, Langbeen A, Goovaerts IG, Leroy JL (April 2010). "Xenotransplantation in immunodeficient mice to study ovarian follicular development in domestic animals". Theriogenology 73 (6): 740–7. doi:10.1016/j.theriogenology.2009.10.002. PMID 19913288. 
  5. ^ Lan C, Xiao W, Xiao-Hui D, Chun-Yan H, Hong-Ling Y (December 2008). "Tissue culture before transplantation of frozen-thawed human fetal ovarian tissue into immunodeficient mice". Fertil. Steril. 93 (3): 913–919. doi:10.1016/j.fertnstert.2008.10.020. PMID 19108826. 
  6. ^ Van Eyck AS, Bouzin C, Feron O, et al. (March 2010). "Both host and graft vessels contribute to revascularization of xenografted human ovarian tissue in a murine model". Fertil. Steril. 93 (5): 1676–85. doi:10.1016/j.fertnstert.2009.04.048. PMID 19539913. 
  7. ^ Michler, R. 1996. Xenotransplantation: Risks, Clinical Potential, and Future Prospects. EID 2(1). [1]
  8. ^ a b c d e f g Dooldeniya, M., Warrens, A. 2003. Xenotransplantation: where are we today? J R Soc Med; 96: 11-117.[2]
  9. ^ a b c d e f g Taylor, L. 2007. Xenotransplantation. Emedicine online journal. http://www.emedicine.com/med/topic3715.htm
  10. ^ Dooldeniya, M., Warrens, A. 2003. Xenotransplantation: where are we today? J R Soc Med; 96: 11-117. [3]
  11. ^ a b c d e f Candinas, D., Adams, D. 2000. Xenotransplantation: postponed by a millennium? Q J Med; 93: 63-66. http://qjmed.oxfordjournals.org/cgi/content/full/93/2/63?maxtoshow
  12. ^ LaTemple DC, Galili U. 1998. Adult and neonatal anti-Gal response in knock-out mice for alpha1,3galactosyltransferase. Xenotransplantation; 5:191 -196.
  13. ^ Sharma A., Okabe J., Birch P., et al. 1996. Reduction in the level of Gal(alpha1,3)Gal in transgenic mice and pigs by the expression of an alpha(1,2)fucosyltransferase. Proc Natl Acad Sci USA; 93:7190 -7195.
  14. ^ Huang J., Gou D., Zhen C., et al. 2001. Protection of xenogeneic cells from human complement-mediated lysis by the expression of human DAF, CD59 and MCP. FEMS. Immunol Med Microbiol; 31: 203 -209.
  15. ^ Takahashi, T., Saadi, S., Platt, J. 1997. Recent advances in the immunology of xenotransplantation.
  16. ^ a b Abbas, A., Lichtman, A. 2005. Cellular and Molecular Immunology, 5th edition, pp 81, 330-333, 381, 386. Elsevier Saunders, Pennsylvania.
  17. ^ a b Vanderpool, H. 1999. Xenotransplantation: progress and promise. Student BMJ; 12: 422.
  18. ^ Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. 2005. Avian Influenza A (H5N1) Infection in Humans. N Engl J Med;353(13):1374-1385. http://content.nejm.org/cgi/content/full/353/13/1374
  19. ^ a b Takeuchi, Y., Weiss, R. 2000. Xenotransplantation: reappraising the risk of retroviral zoonosis. Current Opinion in Immunology; 12(5): 504-507.
  20. ^ FDA. 2006. Xenotransplantation Action Plan: FDA Approach to the Regulation of Xenotransplantation. Center for Biologics Evaluation and Research. http://www.fda.gov/cber/xap/xap.htm
  21. ^ "The Australian National Health and Medical Research Council's 2005 statement on xenotransplantation" (PDF). Archived from the original on 2008-07-22. http://web.archive.org/web/20080722120810/http://nhmrc.gov.au/about/committees/expert/gtrap/_files/xenotrans.pdf. Retrieved 2008-11-06. 
  22. ^ http://www.lifescientist.com.au/article/329402/xenotransplantation_ban_lifted_australia/
  23. ^ Armstrong, J., Porterfield J., De Madrid, A. 1971. C-type virus particles in pig kidney cell lines. J Gen Virol; 10: 195–198.
  24. ^ a b Patience, C., Takeuchi, Y., Weiss, R. 1997. Infection of human cells by an endogenous retrovirus of pigs. Nat Med; 3: 282–286.
  25. ^ Rogel-Gaillard, C., Bourgeaux, N., Billault, A., Vaiman, M., Chardon, P. 1999. Construction of a swine BAC library: application to the characterization and mapping of porcine type C endoviral elements. Cytogenet Cell Genet; 85: 205–211.
  26. ^ Takeuchi, Y., Patience, C., Magre, S., Weiss, R., Banerjee, P., Le Tissier, P., Stoye, J. 1998. Host range and interference studies of three classes of pig endogenous retrovirus. J Virol; 72: 9986–9991
  27. ^ PETA Media Center: Factsheet: Xenotransplantation
  28. ^ Derdidas, Ihrwir Von. 2009. A More Modest Proposal. Hotel St. George Press. [4]
  29. ^ Vanderpool, H. 1999. Xenotransplantation: progress and promise. Student BMJ; 12: 422. [5]

Further reading

External links

Wikimedia Foundation. 2010.

Игры ⚽ Поможем сделать НИР

Look at other dictionaries:

  • Xenotransplantation — Athymische Maus mit implantierten humanem Prostatakarzinom (LNCaP Zelllinie). Bei einer Xenotransplantation (griechisch ξένος, xénos: Fremder) handelt es sich um die Übertragung von lebens und funktionstüchtigen Zellen oder Zellverbänden… …   Deutsch Wikipedia

  • Xenotransplantation — Transplantation from one species to a foreign one. The rationale for xenotransplantation has been the short supply of human organs for transplantation. Perhaps the most famous case of cross species transplantation was that of a heart from a… …   Medical dictionary

  • Xenotransplantation — Xe|no|trans|plan|ta|ti|on 〈f. 20; Med.〉 Verpflanzung von Tierorganen bei Menschen [<grch. xenon „Fremdes“ + Transplantation] * * * Xe|no|trans|plan|ta|ti|on, die (Med.): Transplantation von Organen, Gewebeteilen auf ein Lebewesen einer anderen …   Universal-Lexikon

  • xenotransplantation — noun Date: 1969 transplantation of an organ, tissue, or cells between two different species • xenotransplant noun …   New Collegiate Dictionary

  • xenotransplantation — xen·o·trans·plan·ta·tion (zĕn ə trăns plăn tāʹshən, zē nə ) n. The surgical transfer of cells, tissues, or especially whole organs from one species to another. * * * …   Universalium

  • xenotransplantation — noun The transplantation of cells, tissues, or whole organs (usually modified) of one species into another species …   Wiktionary

  • Xenotransplantation — 1. Tidsskrift. 2. Transplantation af celler, væv eller organer på tværs af arter. Af: xenos = fremmed, og transplantation = overførsel af væv. eksemplevis arbejdes der på at overføre nerveceller, hjerte og lever fra grise til mennesker …   Danske encyklopædi

  • Xenotransplantation — Xe|no|trans|plan|ta|ti|on 〈f.; Gen.: , Pl.: en; Med.〉 artfremde Transplantation, Transplantieren von Organen od. Geweben von einer Spezies auf die andere (z. B. bei Herztransplantationen) [Etym.: <grch. xenos »fremd« + Transplantation] …   Lexikalische Deutsches Wörterbuch

  • Xenotransplantation — Xe|no|trans|plan|ta|ti|on die; , en: Transplantation, bei der Xenotransplantate verwendet werden (Med.) …   Das große Fremdwörterbuch

  • xenotransplantation — n. implantation of animal organs into human bodies …   English contemporary dictionary

Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”